Incyte (NASDAQ: INCY) — Company Overview, News & Financial Data
Incyte is a biopharmaceutical company focused on developing therapeutics for oncology and inflammation, advancing its product pipeline.
Incyte
Incyte is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics for serious medical conditions. Headquartered in Wilmington, Delaware, the company operates primarily across three core therapeutic areas: hematology, oncology, and inflammation and autoimmunity. Its commercial portfolio includes targeted oral and topical treatments for blood cancers, rare bone marrow disorders, and dermatological conditions. Incyte conducts research and development activities in the United States and Europe, advancing a broad pipeline of small molecules and biologics while maintaining strategic licensing partnerships with pharmaceutical companies worldwide to distribute its therapies across international markets.
Snapshot
Operations
Products and/or services of Incyte
- Hematology Therapies: Focuses on targeted prescription treatments for blood disorders, including oral Janus kinase inhibitors indicated for myelofibrosis, polycythemia vera, and graft-versus-host disease, representing a primary commercial revenue driver across clinical oncology markets.
- Dermatology and Autoimmune Treatments: Develops and commercializes topical JAK inhibitor formulations targeting specific dermatological and autoimmune conditions, including nonsegmental vitiligo and mild-to-moderate atopic dermatitis across major commercial healthcare markets globally.
- Targeted Oncology Products: Offers precision therapies for solid tumors and hematological malignancies, including targeted kinase inhibitors and monoclonal antibodies for patients with cholangiocarcinoma and relapsed or refractory diffuse large B-cell lymphoma.
- Out-Licensing and Global Partnerships: Collaborates with international biopharmaceutical partners to generate royalty income and milestone payments from global sales of co-developed targeted therapies in territories outside primary commercial markets.
- Clinical Research and Development Pipeline: Advances early-to-late-stage clinical trial programs focused on novel small molecules, bispecific antibodies, and immuno-oncology mechanisms to expand therapeutic indications across underserved oncology and autoimmune disease areas.
- Global Commercial Infrastructure: Maintains integrated commercial, sales, and medical affairs operations across North America, Europe, and Asia-Pacific to market, distribute, and support proprietary biopharmaceutical products to healthcare providers.
Incyte executive team
- William J. MeuryCEO & Director
- Pablo J. CagnoniPresident and Global Head of R&D
- Thomas TrayPrincipal Financial Officer, VP of Finance & Chief Accounting Officer
- Steven H. SteinExecutive VP, Head of Late-stage Development & Chief Medical Officer
- Mohamed Khairie IssaExecutive Vice President & Head of U.S. Commercial
- Suketu P. UpadhyayExecutive VP & CFO
- Michael James MorrisseyExecutive VP & Head of Global Technical Operations
- Alexis SmithVP & Head of Investor Relations
- Richard A. HoffmanExecutive VP, General Counsel & Secretary
- Pamela M. MurphyVP of Investor Relations & Corporate Communications
Latest news about Incyte
Halozyme and Incyte partner for drug delivery deal
United StatesIncyte reports 81% bleeding reduction in VWD study
United StatesIncyte completes $1.25B acquisition of Vega Therapeutics
United StatesIncyte receives positive CHMP opinion for Opzelura in moderate atopic dermatitis
United StatesIncyte's Minjuvi gains Japan approval with 71.4% response
United StatesIncyte to acquire Vega Therapeutics for $1.25B to expand hematology pipeline
United States
Key financials
Reported results for Incyte , in USD.
- Market cap
- 23.7B
- Revenue (TTM)
- 5.8B
- P/E ratio
- 14.9
- EPS (diluted, TTM)
- 7.8
- Dividend yield
- —
- Profit margin
- 27.7%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 5.1B | 1.3B | 1.3B | |
| 4.2B | 101.3M | 32.6M | |
| 3.7B | 655.4M | 597.6M | |
| 3.4B | 591.6M | 340.7M |